The company showcased its Xpress.Cardiac, Xpress3.Cardiac, and Xpress/Xact.Bone solutions, which provide value to physicians, technologists, patients, administrators and radiopharmaceutical suppliers. UltraSPECT’s exclusive reconstruction algorithms allow for high imaging quality at half or quarter time or simultaneously at half dose and half time. The system provides numerous benefits: safer and shorter scans, enhanced patient comfort, and increased patient throughput without changes in the existing workflow.
At a fraction of the cost of a brand new camera, UltraSPECT allows healthcare organizations to comply with the American Society of Nuclear Cardiology 2014 dose-reduction guidelines.
“The initiative to lower the dose is driven by the industry looking for a safer and more cost-effective way to serve patients, who, in their turn, become increasingly sophisticated when it comes to medical solutions proposed to them,” said Yossi Srour, president and CEO of UltraSPECT. “They request lower dose, and we are pleased to offer a safer imaging solution that answers the needs of all in this process.”
For more information, visit UltraSPECT.
Get AXIS e-newsletters free. Subscribe here.
